Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity of KRAS Mutation Status in Rectal Cancer.

PloS one - 1 Jan 2016

Jo Peter, König Alexander, Schirmer Markus, Kitz Julia, Conradi Lena-Christin, Azizian Azadeh, Bernhardt Markus, Wolff Hendrik A, Grade Marian, Ghadimi Michael, Ströbel Philipp, Schildhaus Hans-Ulrich, Gaedcke Jochen

Abstract excerpt

INTRODUCTION: Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there is intra-specimen KRAS heterogeneity prior to and upon preoperative chemoradiotherapy (CRT), and if...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Neoplasm, Residual

Share to Neoplasm Staging

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27064574
DOI: 10.1371/journal.pone.0153278
PMCID: PMC4827807

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity of KRAS Mutation Status in Rectal Cancer.PMID 27064574Read ↗

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.Semantic proximity Read ↗

Intra-tumoral Heterogeneity of<i>KRAS</i>and<i>BRAF</i>Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample TestingSemantic proximity Read ↗

Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.Semantic proximity Read ↗

Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer.Semantic proximity Read ↗

Intra-tumoral genomic heterogeneity in rectal cancer: mutational status is dependent on preoperative biopsy depth and location.  Semantic proximity Read ↗

Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer.Semantic proximity Read ↗

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.Semantic proximity Read ↗

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.Semantic proximity Read ↗

High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.Semantic proximity Read ↗

KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.Semantic proximity Read ↗

KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.Semantic proximity Read ↗

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.